GSK plc (GSK, GSK.L) announced the European Medicine Agency's Committee for Medicinal Products for Human Use or CHMP has recommended ...

EMA’s human medicines committee recommends approval of GSK’s single-vial, fully liquid presentation of Menveo meningococcal vaccine: London, UK Wednesday, September 25, 2024, ...

If approved, the fully liquid presentation will offer healthcare providers an option that does not require reconstitution of Menveo (MenACWY vaccine) before use · Marketing authorisation in EU ...

The London-based pharmaceutical company said the committee recommended its new single-vial, fully liquid presentation of its invasive meningococcal disease vaccine Menveo. The recommendation is ...

Pharmaceutical and biotechnology company GSK said on Tuesday that the European Medicine Agency has recommended meningococcal ...

GSK PLC on Tuesday announced a new positive opinion from the EU's European Medicine Agency's Committee for Medicinal ... Subscribe now to see this Premium News article from Alliance News ...

The new vaccine is a combination of GSK’s already-approved vaccines Bexsero and Menveo and is designed to protect against meningitis and blood poisoning caused by the A, B, C, W, and Y ...

That hasn’t stopped Bexsero’s steady growth, with sales approaching the $1 billion threshold last year, while Menveo added another $430 million. Pfizer has been something of an also-ran in the ...

The European stock markets closed higher in Tuesday trading as the Stoxx Europe 600 rose 0.58%, the Swiss Market Index climbed 0.70%, France's CAC increased 1.28%, the FTSE in London gained 0.28%, and ...